EDAP to Present at Jefferies Global Healthcare Conference in London
Company to Present and Host 1×1 Investor Meetings on Tuesday, November 18th, 2025
AUSTIN, Texas, November 4, 2025 — EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to present and host 1×1 investor meetings at the upcoming Jefferies Global Healthcare Conference, which is being held November 18-20, 2025, in London, United Kingdom.
Date: Tuesday, November 18th
Presentation Time: 4:30-4:55 pm GMT
Format: Presentation and 1×1 investor meetings
Location: Waldorf – Aldwych, Entresol Level
Webcast: https://wsw.com/webcast/jeff332/edap/1817998
The live and archived webcast of the presentation can be accessed in the Investors section of the Company’s website here.
About EDAP TMS SA
A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics and precise non-invasive energy delivery, EDAP introduced the Focal One® in Europe and in the U.S. as the leading prostate focal therapy controlled by urologists with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit https://focalone.com/.
Company Contact
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
legal@focalone.com
Investor Contact
John Fraunces
LifeSci Advisors, LLC
(917) 355-2395
jfraunces@lifesciadvisors.com


Đề xuất
Moonbird Claims Evaluated: Guided Breathing Therapy Device for Meditation-Like Calming Benefits for Relaxation & Sleep Support
Essential Pharma 旗下公司 Renaissance Pharma Limited 用于治疗高危神经母细胞瘤的 Daretabart (hu1418K322A) 获得 FDA 快速通道认定,并通过 IND 审评
Provectus Biopharmaceuticals to Hold 2026 Annual Meeting of Stockholders at Perkins Place, Its Planned New Headquarters in Knoxville, Tennessee
Enara Bio Presents First-in-Class DARKFOX-Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential in Solid Tumor Immunotherapy
Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026
Craft Green This Earth Day: Monport Mega S Redefines Sustainable Making with Smart Laser Technology